Abstract
Pleural diseases are a commonly encountered problem by general physicians and chest specialists alike. Despite this, there has been a lack of research over the last few decades in this important field. This review focuses on new developments in the management of pleural effusions. We have restricted our attention, in the main, to randomised controlled trials. The review is evidence-based with practical suggestions from the authors to practicing clinicians. Specific areas focused on are pleural infection and malignant pleural disease. In pleural infection, the importance of pleural pH is emphasised and we have incorporated the latest evidence on the use of fibrinolytics from the recent multi-centre randomised controlled MIST trial. In malignant pleural effusion, the best way of obtaining closed pleural biopsy is discussed. With regard to pleurodesis, recent data on the importance of knowing your talc particle size is highlighted, as well as the role of fibrinolytics, thoracoscopy and when to use Pleurx catheters. Finally, the latest developments on newer diagnostic markers such as mesothelin in mesothelioma and newer anti-pleural agents such as transforming growth factor-beta (TGF-β) and vascular endothelial growth factor (VEGF) antagonists have been reviewed.
Keywords: Pleural effusion, malignant pleural disease, pleural infection, new developments
Current Respiratory Medicine Reviews
Title: New Developments in the Management of Pleural Effusions
Volume: 2 Issue: 3
Author(s): Andrew RL Medford and Nick A. Maskell
Affiliation:
Keywords: Pleural effusion, malignant pleural disease, pleural infection, new developments
Abstract: Pleural diseases are a commonly encountered problem by general physicians and chest specialists alike. Despite this, there has been a lack of research over the last few decades in this important field. This review focuses on new developments in the management of pleural effusions. We have restricted our attention, in the main, to randomised controlled trials. The review is evidence-based with practical suggestions from the authors to practicing clinicians. Specific areas focused on are pleural infection and malignant pleural disease. In pleural infection, the importance of pleural pH is emphasised and we have incorporated the latest evidence on the use of fibrinolytics from the recent multi-centre randomised controlled MIST trial. In malignant pleural effusion, the best way of obtaining closed pleural biopsy is discussed. With regard to pleurodesis, recent data on the importance of knowing your talc particle size is highlighted, as well as the role of fibrinolytics, thoracoscopy and when to use Pleurx catheters. Finally, the latest developments on newer diagnostic markers such as mesothelin in mesothelioma and newer anti-pleural agents such as transforming growth factor-beta (TGF-β) and vascular endothelial growth factor (VEGF) antagonists have been reviewed.
Export Options
About this article
Cite this article as:
RL Medford Andrew and Maskell A. Nick, New Developments in the Management of Pleural Effusions, Current Respiratory Medicine Reviews 2006; 2 (3) . https://dx.doi.org/10.2174/157339806778018926
DOI https://dx.doi.org/10.2174/157339806778018926 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial [Hot Topic: The Therapeutic Potential of Ribonucleases (Guest Editor: Urich Arnold) ]
Current Pharmaceutical Biotechnology The Role of PET/CT and SPECT/CT in Oncology Drug Development
Current Molecular Imaging (Discontinued) The Ubiquitin-Proteasome System (UPS) and the Mechanism of Action of Bortezomib
Current Pharmaceutical Design Regulation and Quantification of Cellular Mitochondrial Morphology and Content
Current Pharmaceutical Design Development of Vasculature Targeting Strategies for the Treatment of Chronic Inflammatory Diseases
Current Drug Targets - Inflammation & Allergy Prognostic and Therapeutic Implications of MicroRNA in Malignant Pleural Mesothelioma
MicroRNA Applications of Nanocarbons in Bio-Medical Devices
Recent Innovations in Chemical Engineering Reversing Aberrant Methylation Patterns in Cancer
Current Medicinal Chemistry Anti-cancer Immunotoxins, Challenges, and Approaches
Current Pharmaceutical Design Recent Advances in Small Molecule Inhibitors of VEGFR and EGFR Signaling Pathways
Current Topics in Medicinal Chemistry Targeting the Mitochondrial Electron Transport Chain Complexes for the Induction of Apoptosis and Cancer Treatment
Current Pharmaceutical Biotechnology Adenoviral Vector-Mediated Gene Transfer for Human Gene Therapy
Current Gene Therapy Synergistic Interaction of Telomerase-Specific Oncolytic Virotherapy and Chemotherapeutic Agents for Human Cancer
Current Pharmaceutical Biotechnology A Review of Pharmacological Treatment Options for Lung Cancer: Emphasis on Novel Nanotherapeutics and Associated Toxicity
Current Drug Targets Use of Anti-Cancer Drugs, Mitocans, to Enhance the Immune Responses against Tumors
Current Pharmaceutical Biotechnology Anticancer Properties of the IL-12 Family - Focus on Colorectal Cancer
Current Medicinal Chemistry Nanoparticles for Tumor Targeted Therapies and Their Pharmacokinetics
Current Drug Metabolism TRAIL Gene Therapy: From Preclinical Development to Clinical Application
Current Gene Therapy Drug Targets to Pro-Angiogenetic Factors with Special Reference to Primary Peritoneal Mesothelioma
Endocrine, Metabolic & Immune Disorders - Drug Targets Stem Cell Transplantation for Hematological Malignancies: Prospects for Personalized Medicine and Co-therapy with Mesenchymal Stem Cells
Current Pharmacogenomics and Personalized Medicine